Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus
Xiaolan Zhou,Rumeng Chen,Yichen Cai,Qiu Chen
DOI: https://doi.org/10.2147/dmso.s447784
2024-02-08
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Xiaolan Zhou, 1 Rumeng Chen, 2 Yichen Cai, 1 Qiu Chen 1 1 Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China; 2 School of Life Sciences, Beijing University of Chinese Medicine, Beijing, People's Republic of China Correspondence: Qiu Chen, Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39, Shierqiao Road, Chengdu, Sichuan, People's Republic of China, Tel +86 18981885702, Fax +86 28-87765517, Email Purpose of Review: The aim of this review is to summarize the role of gastrointestinal microbiome (GM) in the development of type 2 diabetes mellitus (T2DM). Besides, we discuss the feasibility of applying FMT in the treatment of T2DM and propose a series of processes to refine the use of FMT in the treatment of T2DM. Recent Findings: T2DM is a metabolic disease which is connected with the GM. According to many researches, GM can produce a variety of metabolites such as bile acid, short chain fatty acids, lipopolysaccharides and trimethylamine oxide which play an important role in metabolism. FMT is a method to regulate GM and has been observed to be effective in the treatment of metabolic diseases such as T2DM in some mouse models and people. However, there is still a lack of direct evidence for the use of FMT in the treatment of T2DM, and the process of FMT is not standardized. Summary: Dysregulation of GM is closely related to the development of T2DM. Promoting the conversion of GM in T2DM patients to normal population through FMT can reduce insulin resistance and lower their blood glucose level, which is an optional treatment for T2DM patients in the future. At present, the feasibility and limitations of applying FMT to the treatment of T2DM need to be further studied. Keywords: fecal microbiota transplantation, type 2 diabetes mellitus, gastrointestinal microbiome, treatment Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, which progressively involves systemic micro- and macro-vasculature, leading to disease of the aorta, retina, kidneys and peripheral nerves and an increased risk of cardiovascular and cerebrovascular complications. 1 According to IDF Diabetes Atlas, 537 million adults are living with diabetes worldwide, and this number is predicted to rise to 643 million by 2030 and 783 million by 2045. In addition, 541 million adults have Impaired Glucose Tolerance (IGT), which places them at high risk of type 2 diabetes. 2 The pathogenesis of T2DM is based on insulin resistance and defective insulin secretion. Studies have shown that adipose tissue dysfunction, chronic inflammation of the intestinal tract, abnormal mitochondrial function and dysregulation of the hypothalamic-pituitary-adrenal axis are directly or indirectly involved in these processes. 1,3 In recent years, a new direction of research has been observed: gastrointestinal microbiome (GM). 4 GM is one of the important regulators of energy metabolism and substrate metabolism in the human body. 5–7 Disturbances in GM may lead to metabolic imbalances in the body, which can lead to a variety of metabolic disorders such as chronic inflammation, insulin resistance, and obesity. 8–10 GM is similarly regulated by signaling molecules from the body, which can contribute to the development of T2DM. 11,12 Thus, disturbances in GM have been recognized as a potential contributor to the increased prevalence of diabetes. 13 According to some studies, GM can participate in the control of bile acid (BA) metabolism, and its metabolites such as short chain fatty acids (SCFAs), lipopolysaccharides (LPS) and trimethylamine oxide (TMAO) also play a significant function in human metabolism, which can be a new target for the treatment of T2DM. 14–17 Therefore, regulating the composition of the GM in patients with T2DM may suggest a new therapeutic idea. 18 The use of a variety of prebiotic and probiotic strains in patients with T2DM appears to reverse ecological dysregulation and restore the functional integrity of the gut. 19 In other words, it is important to maintain bacterial diversity and abundance, rather than stimulating only one bacterial genus. 20 Fecal microbiota transplantation (FMT) has been used in the treatment of colitis due to recurrent Clostridium Difficile Infection (rCDI) initially. It processes feces from healthy donors and transports them to the recipient via endoscopy, enemas and capsules, relying on the transplanted GM to compete with Clostridium difficile for the dominant strain, changing the abundance of the GM composition and thus -Abstract Truncated-
endocrinology & metabolism